Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes

Table 1 Comparisons of ΔMBCI, ΔLNΔI30/ΔG30, ΔP/I and ΔAUCins levels after 8-week treatment between liraglutide and metformin group

Variable	Liraglutide	Metformin	Difference	P value
ΔMBCI	11.1 (2.81, 43.08)	0.00 (− 8.16, 10.47)	6.53 (− 1.75, 14.02)	0.017
ΔLNΔI30/ΔG30	0.44 (0.04, 0.85)	− 0.09 (− 0.33, 0.36)	0.21 (− 0.15, 0.68)	0.049
ΔP/I	− 0.05 (− 0.09, − 0.03)	− 0.02 (− 0.04, − 0.01)	− 0.03 (− 0.06, − 0.01)	0.026
ΔAUCins (mIU/L)	117 (− 8, 376)	− 21 (− 341, 109)	39 (− 33, 227)	0.013

Data are expressed as median (interquartile rang). Deltas (Δ) are presented as the difference of variables before and after treatment
MBCI, modified B cell function index; ΔI30/ΔG30, [(insulin at 30 min) − (insulin at 0 min)]/[(glucose at 30 min) − (glucose at 0 min)]; P/I, proinsuin to insulin ratio; AUCins, insulin area under the curve; LN, log-transformed

ISSN: 1758-5996